Jason Porter, MD, highlights the implications of recent data to emerge following the use of EGFR TKIs in the adjuvant setting, the importance of the potential upcoming FDA approval of osimertinib with chemotherapy in EGFR-positive non–small cell lung cancer, and more.
Experts share treatment experiences with osimertinib and afatinib, the potential role of immunotherapy, and ongoing investigations with ADCs and emerging TKIs for patients with uncommon EGFR mutations.